ES2945407T3 - Péptido sintético termorresistente del veneno de escorpión y aplicaciones del mismo - Google Patents
Péptido sintético termorresistente del veneno de escorpión y aplicaciones del mismo Download PDFInfo
- Publication number
- ES2945407T3 ES2945407T3 ES16905684T ES16905684T ES2945407T3 ES 2945407 T3 ES2945407 T3 ES 2945407T3 ES 16905684 T ES16905684 T ES 16905684T ES 16905684 T ES16905684 T ES 16905684T ES 2945407 T3 ES2945407 T3 ES 2945407T3
- Authority
- ES
- Spain
- Prior art keywords
- svhrsp
- scorpion venom
- scorpion
- amino acid
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 56
- 239000002795 scorpion venom Substances 0.000 title claims abstract description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 16
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 15
- 206010015037 epilepsy Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
- 229920001184 polypeptide Polymers 0.000 abstract description 20
- 241001481692 Mesobuthus martensii Species 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 abstract description 6
- 206010012289 Dementia Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 35
- 239000000243 solution Substances 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 241000244206 Nematoda Species 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000239226 Scorpiones Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000035605 chemotaxis Effects 0.000 description 10
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 10
- 229960001416 pilocarpine Drugs 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000004949 mass spectrometry Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 231100000668 minimum lethal dose Toxicity 0.000 description 7
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 210000001178 neural stem cell Anatomy 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000001037 epileptic effect Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 238000007885 magnetic separation Methods 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000032459 dedifferentiation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000004295 hippocampal neuron Anatomy 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 231100000636 lethal dose Toxicity 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000002435 venom Substances 0.000 description 4
- 231100000611 venom Toxicity 0.000 description 4
- 210000001048 venom Anatomy 0.000 description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000008730 Nestin Human genes 0.000 description 3
- 108010088225 Nestin Proteins 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002243 primary neuron Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008672 reprogramming Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001360 collision-induced dissociation Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 101150089730 gly-10 gene Proteins 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
- 241000416098 Heliotropium angiospermum Species 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000204 effect on epilepsy Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 238000002418 nanoflow liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- -1 that is Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008280 toxic mechanism Effects 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Insects & Arthropods (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610645111.7A CN106220713B (zh) | 2016-08-08 | 2016-08-08 | 一种蝎毒耐热合成肽及其用途 |
| PCT/CN2016/112078 WO2018028117A1 (zh) | 2016-08-08 | 2016-12-26 | 一种蝎毒耐热合成肽及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2945407T3 true ES2945407T3 (es) | 2023-07-03 |
Family
ID=57547837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16905684T Active ES2945407T3 (es) | 2016-08-08 | 2016-12-26 | Péptido sintético termorresistente del veneno de escorpión y aplicaciones del mismo |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10442837B2 (enExample) |
| EP (1) | EP3505530B1 (enExample) |
| JP (1) | JP6483858B2 (enExample) |
| CN (1) | CN106220713B (enExample) |
| CA (1) | CA2984569C (enExample) |
| ES (1) | ES2945407T3 (enExample) |
| WO (1) | WO2018028117A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106220713B (zh) * | 2016-08-08 | 2017-09-01 | 大连医科大学 | 一种蝎毒耐热合成肽及其用途 |
| CN109232718B (zh) * | 2018-11-09 | 2020-04-14 | 泰安市启航生物科技有限公司 | 一种合成肽sp2及其应用 |
| CN111647051B (zh) * | 2019-03-04 | 2022-02-01 | 中国医科大学 | 一种基于钠通道结构的短肽及其应用 |
| CN111896651B (zh) * | 2020-07-30 | 2021-04-23 | 山东大学 | 一种白眉蝮蛇蛇毒类凝血酶特征多肽及其应用 |
| CN114028537B (zh) * | 2021-11-27 | 2024-03-29 | 上海万锦医药科技有限公司 | 一种含有svhrsp蝎毒肽的药物组合物及其制备方法 |
| CN117224655B (zh) * | 2023-09-14 | 2024-05-14 | 大连医科大学 | 蝎毒耐热合成肽(svhrsp)在制备治疗肠道炎症的药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171595C (zh) * | 2001-02-19 | 2004-10-20 | 大连高新园区全国高技术产业化微生态中试基地 | 获取无毒有效蝎毒的生产工艺及由该工艺制备的治疗癫痫的药物 |
| US20030235902A1 (en) * | 2001-12-13 | 2003-12-25 | Kazuhiko Ishikawa | Heat-resistant thioredoxin and related enzymes |
| CN100465272C (zh) * | 2002-01-18 | 2009-03-04 | 中国科学院上海有机化学研究所 | 重组东亚马氏钳蝎毒rBmKaIT1的基因工程 |
| CN100516217C (zh) * | 2004-09-22 | 2009-07-22 | 山西大学 | 一种人工合成的蝎氯离子通道神经毒素基因-rBmK CTa |
| US20070191272A1 (en) * | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| CN1817902A (zh) * | 2006-03-07 | 2006-08-16 | 山西大学 | 一种重组蝎昆虫毒素及其可溶性表达和纯化方法 |
| CN101450966B (zh) * | 2007-11-29 | 2012-06-27 | 武汉摩尔生物科技有限公司 | 一种抗耐药菌的多肽及用途 |
| CN101284870B (zh) * | 2008-06-03 | 2011-09-14 | 武汉大学 | 一种抗麻疹病毒和人免疫缺陷病毒的多肽及用途 |
| CN103304630B (zh) * | 2012-03-07 | 2014-09-17 | 中国科学院大连化学物理研究所 | 东亚钳蝎蝎毒中的gpcr活性多肽及其提取分离和应用 |
| CN104341495A (zh) | 2013-07-31 | 2015-02-11 | 张万琴 | 一种蝎毒耐热多肽和制备方法及其应用 |
| CN106220713B (zh) * | 2016-08-08 | 2017-09-01 | 大连医科大学 | 一种蝎毒耐热合成肽及其用途 |
-
2016
- 2016-08-08 CN CN201610645111.7A patent/CN106220713B/zh active Active
- 2016-12-26 WO PCT/CN2016/112078 patent/WO2018028117A1/zh not_active Ceased
- 2016-12-26 ES ES16905684T patent/ES2945407T3/es active Active
- 2016-12-26 CA CA2984569A patent/CA2984569C/en active Active
- 2016-12-26 EP EP16905684.3A patent/EP3505530B1/en active Active
- 2016-12-26 JP JP2017554073A patent/JP6483858B2/ja active Active
-
2017
- 2017-11-01 US US15/800,802 patent/US10442837B2/en active Active
-
2019
- 2019-09-17 US US16/573,495 patent/US10870680B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2984569C (en) | 2019-10-22 |
| EP3505530A1 (en) | 2019-07-03 |
| JP2018529626A (ja) | 2018-10-11 |
| US10442837B2 (en) | 2019-10-15 |
| JP6483858B2 (ja) | 2019-03-13 |
| US10870680B2 (en) | 2020-12-22 |
| US20180066019A1 (en) | 2018-03-08 |
| CA2984569A1 (en) | 2018-02-08 |
| EP3505530A4 (en) | 2020-04-29 |
| US20200002381A1 (en) | 2020-01-02 |
| WO2018028117A1 (zh) | 2018-02-15 |
| EP3505530B1 (en) | 2023-02-22 |
| CN106220713B (zh) | 2017-09-01 |
| CN106220713A (zh) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2945407T3 (es) | Péptido sintético termorresistente del veneno de escorpión y aplicaciones del mismo | |
| Zhou et al. | Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways | |
| Guan et al. | MG53 attenuates lipopolysaccharide-induced neurotoxicity and neuroinflammation via inhibiting TLR4/NF-κB pathway in vitro and in vivo | |
| da Conceição Rivanor et al. | A lectin from the green seaweed Caulerpa cupressoides reduces mechanical hyper-nociception and inflammation in the rat temporomandibular joint during zymosan-induced arthritis | |
| Choi et al. | Cistanches Herba enhances learning and memory by inducing nerve growth factor | |
| Xiong et al. | Administration of SB239063, a potent p38 MAPK inhibitor, alleviates acute lung injury induced by intestinal ischemia reperfusion in rats associated with AQP4 downregulation | |
| JP2019530750A (ja) | アミノ酸組成物及びその使用 | |
| Gu et al. | Piperlongumine attenuates experimental autoimmune encephalomyelitis through inhibition of NF-kappaB activity | |
| Cristina Ferraz et al. | The effect of lupane triterpenoids (Dipteryx alata Vogel) in the in vitro neuromuscular blockade and myotoxicity of two snake venoms | |
| ES2384385T3 (es) | Nuevo uso de la proteína factor antisecretor | |
| BG98426A (bg) | Пептиди с органо-защитна активност,метод за тяхното получаване и приложението им за лечение | |
| US20240034752A1 (en) | Artificial short interfering peptide for the phosphorylation substrate of dapk1 and its pharmaceutical applications | |
| ES2637807T3 (es) | Extracto de rhizoma coptidis y uso novedoso del mismo en el tratamiento de enfermedad respiratoria | |
| KR101625502B1 (ko) | 대장상피세포의 성장을 촉진하는 신규 스콜로펜드라신-4 펩타이드 및 그의 조성물 | |
| BRPI0720874A2 (pt) | Peptídeos bioativosa curtos para modulação celular e imunológica. | |
| CN102088992A (zh) | 肽基二酰基甘油酯 | |
| CN106074560A (zh) | 覆盆子提取物的应用 | |
| CN104083420B (zh) | 牛膝活性提取物及其制备方法与用途 | |
| KR20150041298A (ko) | 진토닌을 유효성분으로 함유하는 신경전구세포 증식 또는 신경세포 신생 촉진용 조성물 | |
| WO2012002762A2 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 | |
| Choi et al. | Differential effects of the steaming time and frequency for manufactured red Liriope platyphylla on nerve growth factor secretion ability, nerve growth factor receptor signaling pathway and regulation of calcium concentration | |
| Bawankule et al. | An in-vivo study of the immunomodulatory activity of coumarinolignoids from Cleome viscosa | |
| Hu et al. | Synthesis of peptides of Carapax Trionycis and their inhibitory effects on TGF-β1–induced hepatic stellate cells | |
| ES2524564T3 (es) | Identificación de nuevas toxinas antagonistas de canales de calcio de tipo T de aplicación analgésica | |
| ES2281195T3 (es) | Factores inmunomoduladores para el tratamiento inmunosupresor y antialergico. |